Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro
LEVERKUSEN, Germany (Reuters) - Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion).
The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.
Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.
(Reporting by Frank Siebelt; Writing by Ludwig Burger)
- Tweet this
- Share this
- Digg this
Trending On Reuters
In the middle of a bustling village hall in Myanmar's Kayin state, a government health worker pricks the finger of a child to extract a tiny drop of blood for a malaria test. A scene unthinkable just a few years ago, it is now commonplace in an area that used to be blighted by armed conflict between the government and soldiers from ethnic groups. Full Article